# Sagar Lonial

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sagar-lonial/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68,917 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 119 |
| i10-index | 506 |
| OpenAlex ID | https://openalex.org/A5023276777 |
| ORCID iD | https://orcid.org/0000-0002-8322-9323 |
| Works | 1,531 |

## Researcher papers

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-combination-therapy-in-patients-with/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma](https://scholariq.org/papers/triplet-therapy-transplantation-and-maintenance-until-progression-in-myeloma/)
- [Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial](https://scholariq.org/papers/carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth](https://scholariq.org/papers/prevention-of-dietary-fat-fueled-ketogenesis-attenuates-braf-v600e-tumor-growth/)
- [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](https://scholariq.org/papers/international-myeloma-working-group-guidelines-for-the-management-of-multiple/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Ubiquitin and proteasome pathways](https://scholariq.org/topics/ubiquitin-and-proteasome-pathways-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.